On the use of intravenous metronidazole for severe and complicated Clostridioides difficile infection: a review and meta-analysis.

Le infezioni in medicina Pub Date : 2024-03-01 eCollection Date: 2024-01-01 DOI:10.53854/liim-3201-3
Giuseppe Pipitone, Guido Granata, Massimo Sartelli, Andrea Gizzi, Claudia Imburgia, Laura Marsala, Antonio Cascio, Chiara Iaria
{"title":"On the use of intravenous metronidazole for severe and complicated <i>Clostridioides difficile</i> infection: a review and meta-analysis.","authors":"Giuseppe Pipitone, Guido Granata, Massimo Sartelli, Andrea Gizzi, Claudia Imburgia, Laura Marsala, Antonio Cascio, Chiara Iaria","doi":"10.53854/liim-3201-3","DOIUrl":null,"url":null,"abstract":"<p><p>The European Society of Clinical Microbiology and Infectious Disease (ESCMID) has advised against the use of metronidazole for fulminant <i>Clostridioides difficile</i> (<i>C. difficile</i>) infection (CDI) in their latest guidelines. They suggest using oral vancomycin alone instead. This recommendation is based on a few retrospective studies, which have multiple biases. We evaluated the three studies that led ESCMID to advise against intravenous metronidazole for fulminant CDI and performed a meta-analysis. The meta-analysis revealed a mild (2.7%), not statistically significant (p=0.8) difference in mortality between the two groups. The high heterogeneity (I<sup>2</sup>= 89%) should also be noted. The decision to add or remove metronidazole should be discussed in the near future. In the meantime, combination therapy could be a cautious treatment for fulminant CDI.</p>","PeriodicalId":502111,"journal":{"name":"Le infezioni in medicina","volume":"32 1","pages":"20-24"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10917561/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Le infezioni in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53854/liim-3201-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The European Society of Clinical Microbiology and Infectious Disease (ESCMID) has advised against the use of metronidazole for fulminant Clostridioides difficile (C. difficile) infection (CDI) in their latest guidelines. They suggest using oral vancomycin alone instead. This recommendation is based on a few retrospective studies, which have multiple biases. We evaluated the three studies that led ESCMID to advise against intravenous metronidazole for fulminant CDI and performed a meta-analysis. The meta-analysis revealed a mild (2.7%), not statistically significant (p=0.8) difference in mortality between the two groups. The high heterogeneity (I2= 89%) should also be noted. The decision to add or remove metronidazole should be discussed in the near future. In the meantime, combination therapy could be a cautious treatment for fulminant CDI.

关于使用静脉注射甲硝唑治疗严重和复杂的艰难梭菌感染:综述和荟萃分析。
欧洲临床微生物学和传染病学会(ESCMID)在其最新指南中建议不要使用甲硝唑治疗难辨梭状芽孢杆菌感染(CDI)。他们建议仅使用口服万古霉素。这一建议是基于几项回顾性研究提出的,这些研究存在多种偏差。我们评估了导致 ESCMID 建议不静脉注射甲硝唑治疗暴发性 CDI 的三项研究,并进行了荟萃分析。荟萃分析结果显示,两组死亡率差异轻微(2.7%),无统计学意义(P=0.8)。此外,还应注意高度异质性(I2= 89%)。应在不久的将来讨论添加或去除甲硝唑的决定。同时,联合疗法可能是治疗暴发性 CDI 的一种谨慎方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信